bluebird bio (BLUE) : Zacks Investment Research ranks bluebird bio (BLUE) as 3, which is a Hold recommendation. 9 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 3 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 12 research analysts is 1.5, which indicates as a Strong Buy.
bluebird bio (BLUE) : The highest short term price target forecast on bluebird bio (BLUE) is $117 and the lowest target price is $42. A total of 10 equity analysts are currently covering the company. The average price of all the analysts is $78.5 with a standard deviation of $25.04.
Also, Cantor Fitzgerald initiates coverage on bluebird bio (NASDAQ:BLUE) In a research note issued to the investors, the brokerage major announces price-target of $42 per share.The shares have been rated Hold. The rating by the firm was issued on June 2, 2016.
bluebird bio (NASDAQ:BLUE): After opening at $65.81, the stock dipped to an intraday low of $65.18 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $71.61 and the buying power remained strong till the end. The stock closed at $70.04 for the day, a gain of 11.37% for the day session. The total traded volume was 4,196,411. The stocks close on the previous trading day was $62.89.
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Companys products include Lenti-D, LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy), the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States, Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.